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Abstract
Introduction: Inherited deficiencies of several complement components strongly predispose to systemic lupus
erythematosus (SLE) while deficiencies of complement inhibitors are found in kidney diseases such as atypical
hemolytic uremic syndrome (aHUS).
Methods: The exons of complement inhibitor genes CD46 and CFH (factor H) were fully sequenced using the
Sanger method in SLE patients with nephritis originating from two cohorts from southern and mid Sweden (n =
196). All identified mutations and polymorphisms were then analyzed in SLE patients without nephritis (n = 326)
and in healthy controls (n = 523).
Results: We found nonsynonymous, heterozygous mutations in CFH in 6.1% patients with nephritis, in comparison
with 4.0% and 5.4% in patients without nephritis and controls, respectively. No associations of SLE or nephritis with
common variants in CFH (V62I/Y402H/E936D) were found. Furthermore, we found two nonsynonymous
heterozygous mutations in CD46 in SLE patients but not in controls. The A353V polymorphism, known to affect
function of CD46, was found in 6.6% of nephritis patients versus 4.9% and 6.1% of the non-nephritis SLE patients
and controls. The presence of mutations in CD46 and CFH did not predispose to SLE or nephritis but was
associated with earlier onset of nephritis. Furthermore, we found weak indications that there is one protective and
one risk haplotype predisposing to nephritis composed of several polymorphisms in noncoding regions of CD46,
which were previously implicated in aHUS.
Conclusions: SLE nephritis is not associated with frequent mutations in CFH and CD46 as found in aHUS but these
may be modifying factors causing earlier onset of nephritis.
Introduction
Systemic lupus erythematosus (SLE) is a complex and
heterogeneous autoimmune disease affecting multiple
organs that is characterized by circulating antibodies to
nuclear antigens. Many studies have demonstrated a
strong genetic component to SLE. Several susceptibility
loci have recently been identified in genes encoding
proteins involved in many immunological pathways [1],
including B-cell signaling and development, cytokine
production [2], the type I interferon pathway [3,4], sig-
naling through Toll-like receptors, and neutrophil func-
tion [5].
One of the immune system cascades involved in the
etiopathogenesis of SLE is the complement system.
Complement is a pivotal part of the innate immunity,
protecting the host from infections and participating in
many processes that maintain tissue homeostasis [6]. In
active SLE, immune complex deposition and
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and damage. On the other hand, inherited deficiencies
of complement components such as C1, C2 and C4
strongly predispose to the development of SLE [7]. This
predisposition may be because an intact complement
system is important for opsonization and clearance of
apoptotic and necrotic cells as well as immune com-
plexes, and thus is important for the prevention of auto-
immunity. Additionally, complement is involved in B-
cell maturation, differentiation and tolerance. Comple-
ment is also involved in microbial defense and thus may
be related to SLE exacerbations caused by infections.
Complement is a proteolytic cascade that must be
tightly regulated by several soluble and membrane-
bound inhibitors in order to prevent damage to own tis-
sues. These inhibitors are typically built of complement
control protein (CCP) domains and are mainly encoded
by the RCA (regulators of complement activation) gene
cluster located on the long arm of chromosome 1. The
present study was focused on the genes encoding two
such proteins: CD46 encoding membrane cofactor pro-
tein (MCP), and CFH encoding factor H (FH). MCP is a
cell-bound inhibitor, while FH circulates in blood.
Nearly all human cell types, with the exception of ery-
throcytes, express MCP. This protein acts as a cofactor
to serine proteinase factor I (FI), which is able to
degrade activated complement components C3b and
C4b and thereby to inhibit all pathways of complement.
MCP is composed of four CCP domains followed by a
serine/threonine-rich region, a transmembrane domain
and a small intracellular domain. FH is the major solu-
ble inhibitor of the alternative pathway of complement,
serving as a cofactor to FI in degradation of C3b. FH is
composed of 20 CCP domains, some of which have a
high degree of homology with FH-related proteins 1 to
5 (CFHR1 to CFHR5).
Immune complexes generated in SLE can be passively
trapped in kidney glomeruli but also directly bound to
glomerular structures, causing a wide range of renal
lesions including glomerulonephritis, vasculopathy and
tubulointerstitial disease [8]. Defects in adequate inhibi-
tion of complement caused by inherited or acquired
deficiencies of complement inhibitors could thus be
involved in development and exacerbations of SLE
nephritis. Importantly, inherited defects in complement
inhibitors have already been associated with several kid-
ney diseases. Complete deficiency of FH leads to mem-
branoproliferative glomerulonephritis [9], complete
deficiency of FI results in glomerulonephritis [10], while
heterozygous mutations in genes encoding FH, FI and
MCP result in atypical hemolytic uremic syndrome
(aHUS).
Because of the well-established role of complement in
SLE and the frequent genetic deficiencies of
complement inhibitors in kidney diseases, we hypothe-
sized that mutations or polymorphisms in complement
inhibitors may be associated with SLE, and in particular
with SLE nephritis. Recent genome-wide association stu-
dies have been successful in identifying a number of
SLE-associated genes [1,11-13]. However, these studies
only investigated the effect of single common variants.
In the present study we performed Sanger sequencing of
all exons in the CD46 and CFH genes in two cohorts of
SLE patients collected in southern and mid Sweden to
identify rare variants with a potential effect on SLE and
SLE nephritis. We also analyzed the effect of haplotypes
in CFH and CD46 that are known to affect related traits.
Materials and methods
Patients and controls
We studied two cohorts of unrelated SLE patients origi-
nating from southern Sweden (Lund) and mid Sweden
(Uppsala and Stockholm). The Lund cohort consisted of
164 unselected consecutive SLE patients (21 men/143
women) treated at Skåne University Hospital in Lund
and who agreed to participate in the study. The Uppsala
cohort consisted of 35 SLE patients (four men/31
women) with nephritis and 35 age-matched SLE patients
without nephritis (four men/31 women) all treated at
the University Hospital in Uppsala. The Stockholm
cohort of 288 patients (30 men/258 women) included
unselected consecutive SLE patients treated at Karo-
linska University Hospital in Stockholm. Because of the
very close geographical vicinity of Uppsala and Stock-
holm these two cohorts were pooled into one cohort
(mid Sweden) composed finally of 358 SLE patients (38
men/320 women).
All SLE patients included in the study fulfilled four or
more of the American College of Rheumatology classifi-
cation criteria for SLE [14]. The majority (90.5%) of
patients were Caucasians. The clinical characteristics of
the patients are presented in Table 1. Additionally, 186
(37 men/149 women; southern Sweden) and 70 (8 men/
62 women; Uppsala) healthy blood donors matched for
sex and age were enrolled as controls. Controls (n =
267) originating from Stockholm (20 men/247 women)
were individually sex-matched and age-matched popula-
tion controls.
The local ethic committees of Lund University and
Uppsala University and the regional ethical review board
in Stockholm approved the study, and subjects’ consent
was obtained according to the Declaration of Helsinki.
Genotyping
DNA sequencing using the Sanger dideoxy method was
performed by Polymorphic DNA Technologies (Ala-
meda, CA, USA). All exons including at least 20 flank-
ing intron nucleotides were analyzed for CFH and CD46
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Sweden, n = 153). Thereafter, all exons containing
mutations and polymorphisms identified in CFH and
CD46 in the previous step were also sequenced in SLE
patients without kidney involvement (southern Sweden,
n = 121; mid Sweden, n = 205) as well as controls
(southern Sweden, n = 186; mid Sweden, n =3 3 7 ) .
Finally, some synonymous SNPs in CD46 that were pre-
viously associated with aHUS (rs2796267, rs2796268,
rs1962149, rs859705 and rs7144) and form the
CD46ggaac haplotype were genotyped in all SLE patients
and controls. The mean base call rate for the project
was 99%. All identified SNPs were in Hardy-Weinberg
equilibrium (P > 0.01). The protein numbering system
used includes signal sequences (that is, the first methio-
nine numbered as amino acid 1).
Statistical analysis
Statistical significances of differences in mutation fre-
quencies (listed in Table 2) between SLE patients and
matched controls, between SLE patients with nephritis
and controls, as well as between SLE patients with
nephritis and SLE patients without nephritis were calcu-
lated using Fischer’s exact test. The association of the
mutations in CFH and CD46 with the year of onset of
nephritis was analyzed using the nonparametric Mann-
Whitney test with a two-tailed P value. The calculations
reported included all patients irrespective of their ethnic
background, but similar values were obtained when SLE
patients with nephritis of non-Caucasian origin were
excluded (in total, three nephritis patients carrying
Table 1 Patient characteristics
Southern Sweden Mid Sweden
Number of patients 164 358
Women 143 (87) 320 (89)
Age at diagnosis (years) 46.0 ± 13.2 31.8 ± 13.6
Age at nephritis onset (years) 33.8 ± 14.6 33.6 ± 14.9
SLE duration (years) 16.0 ± 9.7 17.7 ± 11.0
Number of SLE criteria 5.9 (4 to 10) 5.8 (4 to 10)
Malar rash 95 (58) 190 (53)
Discoid rash 61 (37) 59 (16)
Photosensitivity 116 (71) 195 (54)
Oral ulcer 42 (26) 114 (32)
Arthritis 132 (80) 299 (84)
Serositis 88 (54) 158 (44)
Nephritis 43 (26) 153 (43)
Neurological disorder 15 (9) 45 (13)
Hematological disorder 87 (53) 241 (61)
Immunological disorder 121 (74) 265 (74)
Antinuclear antibodies 164 (100) 356 (99)
Data presented as n (%), mean ± standard deviation or mean (range). SLE,
systemic lupus erythematosus.
Table 2 Nonsynonymous mutations found in CD46 and CFH genes
Gene SNP
number
Amino
acid
a
cDNA
ATG + 1
Genomic
DNA
Domain Frequency in SLE
patients with/
without nephritis (%
(n))
Frequency in
controls (%(n))
Disease
association/
function
References
Southern
Sweden
(n = 43)/
(n = 121)
Mid
Sweden
(n = 153)/
(n = 205)
Southern
Sweden
(n = 186)
Mid
Sweden
(n = 337)
CD46 Novel S13F c.38C > T Exon 1 Signal
peptide
0(0)/0(0) 0.6(1)/1.0
(2)
0(0) 0(0) Healthy controls [16]
CD46 Novel A219V c.656C > T Exon 5 CCP3 2.3(1)/0(0) 0(0)/0(0) 0(0) 0(0) n.d.
CD46 rs35366573 A353V c.1058 C > T Exon 11 Trans-
membrane
11.6(5)/5.0
(6)
5.2(8)/3.0
(10)
4.8(9) 6.8(23) aHUS, HELLP, GN
with C3 deposits
and MPGN
[27,39-41]
CFH Novel N29D c.85A > G Exon 2 CCP1 0(0)/0(0) 0(0)/0(0) 0(0) 0.3(1) n.d.
CFH Novel Q400K c.1198C > A Exon 9 CCP7 0(0)/0.8(1) 0(0)/0(0) 0.5(1) 0(0) aHUS [42]
CFH Novel N516K c.1548T > A Exon 11 CCP9 2.3(1)/0(0) 0(0)/0(0) 0(0) 0.3(1) n.d.
CFH Novel N556S c.1667A > G Exon 11 CCP9 0(0)/0.8(1) 0(0)/0(0) 0(0) 0(0) n.d.
CFH Novel Q950H c.2850G > T Exon 18 CCP16 4.7(2)/1.7
(2)
0(0)/0.5(1) 1.6(3) 0.6(2) aHUS [43-45]
CFH Novel F960S c.2879T > A Exon 18 CCP16 0(0)/0(0) 0.7(1)/0(0) 0(0) 0(0) n.d.
CFH rs35274867 N1050Y c.3148A > T Exon 20 CCP18 2.3(1)/2.5
(3)
3.9(6)/2.6
(4)
2.2(4) 4.7(16) aHUS, AMD,
MPGN2
[44,46-48]
CFH rs62625015 Q1076E c.3226C > G Exon 20 CCP18 0(0)/0.8(1) 0.7(1)/0(0) 0(0) 0(0) aHUS [44,48]
All mutations were found in a heterozygous form. The difference in mutation frequencies calculated for systemic lupus erythematosus (SLE) patients versus
controls and for SLE patients with nephritis versus controls or versus SLE patients without nephritis were not statistically significant according to Fischer’s exact
text when calculated for all study participants together or divided into the thee cohorts. aHUS, atypical hemolytic uremic syndrome; AMD, age-related macular
degeneration; CCP, complement control protein; HELLP, hemolysis, elevated liver enzymes, and low platelets; n.d., not described; GN, glomerulonephritis; MPGN,
membranoproliferative glomerulonephritis; MPGN2, membranoproliferative glomerulonephritis type 2.
aNumbering including signal sequence.
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the effect of selected SNPs (frequency higher than 5% in
the studied population) by multiple logistic regression
analysis corrected for sex and center. SNP haplotypes
(frequency higher than 1% in the studied population)
were analyzed by a haplotype-based multiple logistic
regression test corrected for sex and center. All statisti-
cal analyses were performed using PLINK version 1.06
[15]. Max T permutation (10,000 permutations) was
used to determine exact single SNP and SNP haplotype
P values. A two-tailed P value of 0.05 was considered
significant. Only Caucasian patients were included in
the SNP and haplotype analyses (four SLE patients and
46 SLE patients were excluded from the southern and
mid Sweden cohorts, respectively). No adjustments for
multiple comparisons were conducted due to the
exploratory nature of this study in which we tested a
limited number of comparisons based on ap r i o r i
hypotheses.
Results
Mutations and polymorphisms identified in the CD46
gene
Analysis of all CD46 exons in 196 patients with nephri-
tis (southern Sweden, n =4 3 ;m i dS w e d e n ,n = 153)
revealed three nonsynonymous mutations in the coding
exons. One of these mutations (S13F), found in hetero-
zygous form in three SLE patients, was localized in the
signal peptide and previously found in healthy controls
[16] even though the latter was not the case in the cur-
rent study. The other mutation (A219V), found in one
patient, was localized in the CCP3 domain. Further-
more, we found that 11.6% and 5.2% of the patients
with nephritis from the southern and mid Sweden
cohorts carried the A353V polymorphism. In the
patients without nephritis, only 5.0% from southern
Sweden and 3.0% from mid Sweden carried the poly-
morphism; whereas in the control groups, 4.8% and
6.8% of individuals had the polymorphism. The differ-
ences in the A353V polymorphism frequencies between
SLE patients and controls or SLE patients with nephritis
and those without nephritis or healthy controls were
not statistically significant according to Fisher’se x a c t
test (Table 2).
Since several studies identified a specific SNP haplo-
type block spanning CD46 (CD46ggaac), which is overre-
presented in aHUS patients [17,18], we assessed these
SNPs (rs2796267/-652 A > G, rs2796268/-366 A > G,
rs1962149/IVS9-78 G > A, rs859705/IVS12+638 G > A,
rs7144/c.4070 T > C) in our cohorts. Only haplotypes
with frequencies of at least 1% in our cohorts were ana-
lyzed. We found weak indications that the aHUS-asso-
ciated CD46ggaac haplotype could perhaps be protective
for SLE, and in particular for SLE with nephritis, while
the CD46agaac could represent risk haplotype. The
obtained P values, however, were borderline significant
(Table 3).
Mutations and polymorphisms identified in the CFH gene
Analysis of all CFH exons in the SLE patients identified
seven nonsynonymous mutations. In addition, a novel
nonsynonymous mutation (N29D) was found in a
healthy individual. All of the mutations occurred in het-
erozygous state. The Q400K, Q950H, N1050Y and
Q1076E mutations were previously described in patients
with aHUS while the N29D, N516K and N556S muta-
tions appear to have never been reported. In the current
study these three mutations were also found in healthy
individuals at similar frequencies to those in SLE
patients. Analysis of three common coding SNPs in
CFH (V62I/c.184G > A, Y402H/c.1204T > C, E936D/
c.2808G > T) showed no significant association with
SLE or SLE nephritis. Furthermore, no associations of
the haplotypes formed by these SNPs and SLE/SLE
nephritis were found.
Mutations in CD46 and CFH influence age at onset of
nephritis
Mutations found in CD46 and CFH (listed in Table 2)
were found to affect the age at onset of nephritis in the
analyzed SLE patients (Figure 1). The effect was statisti-
cally significant in the larger cohort from mid Sweden
(P = 0.023) and the significance increased when the two
cohorts were analyzed simultaneously (P =0 . 0 0 8 5 ) .T h e
median age of nephritis onset in the SLE patients carry-
ing CD46 and CFH mutations in the combined cohorts
was 24 years (range 12 to 51) compared with 32 years
(range 9 to 84) in the patients free of the mutations.
Thus, even though these mutations do not appear to be
causative factor for nephritis, they may contribute to the
earlier onset of the disease. The multiple regression ana-
lysis did not show significant association between onset
of nephritis and CD46 (rs2796267/-652 A > G,
rs2796268/-366 A > G, rs1962149/IVS9-78 G > A,
rs859705/IVS12+638 G > A, rs7144/c.4070 T > C) or
CFH (V62I/c.184G > A, Y402H/c.1204T > C, E936D/
c.2808G > T) haplotypes.
Discussion
Because complement is intricately involved in SLE and
mutations/polymorphisms in complement inhibitors are
associated with a number of kidney diseases, we
hypothesized that SLE patients, particularly those with
nephritis, may also carry such genetic defects. Kidney
involvement is common in SLE, occurring in up to 25
to 30% of affected Caucasian adults at some stage dur-
ing the course of their disease [19]. In most cases, renal
disease develops within the first 3 years following
Jönsen et al. Arthritis Research & Therapy 2011, 13:R206
http://arthritis-research.com/content/13/6/R206
Page 4 of 9diagnosis. Lupus nephritis still remains a main morbidity
and mortality determinant for patients with SLE and the
current treatment is not satisfactory considering the rate
of success and adverse side effects. If inadequate control
of the complement system caused by genetic predisposi-
tion is involved in SLE nephritis, it could become an
additional indication for use of the emerging comple-
ment inhibitors such as eculizumab, which is a mono-
clonal antibody inhibiting cleavage and activation of C5.
To test our hypothesis we sequenced all exons of the
CD46 and CFH genes in two Swedish cohorts of SLE
patients. Importantly, we could relate the obtained
genetic data to a carefully characterized clinical history of
the patients. Interestingly, even though we did not find
significant association between the presence of mutations
in CD46 and CFH and SLE or SLE nephritis, we observed
that these mutations are associated with a younger age at
onset of glomerulonephritis. The treatment of all patients
with SLE was determined by the clinical manifestations
and was similar according to clinical praxis in the rheu-
matology clinics in southern and mid Sweden, in accor-
dance with EULAR recommendations [20]. There is
Table 3 Associations of haplotypes in CD46 with SLE and SLE nephritis
Frequency SLE nephritis
versus healthy
controls
SLE versus
healthy controls
Cohort CD46
haplotype
All SLE
patients
SLE with
nephritis
SLE without
nephritis
Healthy
controls
Odds
ratio
P
value
Odds
ratio
P
value
Southern
Sweden
GGAAC 0.3068 0.2457 0.3271 0.3512 0.60 0.076 0.81 0.22
Southern
Sweden
AGAAC 0.0901 0.0418 0.1062 0.0573 0.66 0.52 1.53 0.17
Southern
Sweden
GAGGT 0.0901 0.0918 0.0895 0.0627 1.59 0.34 1.41 0.26
Southern
Sweden
AAGGT 0.4974 0.5707 0.473 0.5099 1.3 0.31 0.99 0.93
Mid Sweden GGAAC 0.3242 0.3251 0.3238 0.37 0.81 0.18 0.82 0.090
Mid Sweden AGAAC 0.0892 0.112 0.0723 0.0643 1.93 0.011 1.45 0.093
Mid Sweden GAGGT 0.0636 0.0555 0.0695 0.0647 0.84 0.60 0.96 0.84
Mid Sweden AAGGT 0.5117 0.5005 0.5204 0.4875 1.07 0.68 1.12 0.34
Combined
cohort
GGAAC 0.3184 0.3063 0.3255 0.3633 0.76 0.047 0.82 0.044
Combined
cohort
AGAAC 0.0895 0.096 0.0856 0.0618 1.59 0.056 1.48 0.030
Combined
cohort
GAGGT 0.0725 0.0644 0.0772 0.0641 1 1 1.09 0.64
Combined
cohort
AAGGT 0.5069 0.5161 0.5017 0.4954 1.12 0.38 1.07 0.48
SLE, systemic lupus erythematosus.
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Figure 1 Age at onset of nephritis in systemic lupus erythematosus patients. Median (range) age of nephritis diagnosis for systemic lupus
erythematosus patients with or without FH/CD46 mutations, respectively: (A) Southern Sweden cohort, 28 (15 to 42) years and 33 (10 to 68)
years; (B) mid Sweden cohort, 22 (12 to 51) years and 32 (9 to 84) years; and (C) combined cohort, 24 (12 to 51) years and 32 (9 to 84) years.
Horizontal line, median for each dataset. Statistical significances of differences between patients carrying mutations and those without CD46 and
CFH were evaluated by nonparametric Mann-Whitney test with a two-tailed P value.
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regimens could have affected the time of nephritis onset.
The observed earlier onset of nephritis in SLE patients
carrying mutations in CD46 and CFH is consistent with
a recently published study showing that FH deficiency
accelerates development of lupus nephritis in MRL-lpr
mice, which share many features of human SLE includ-
ing production of autoantibodies and consumptive
hypocomplementemia [21]. Histopathologic findings in
these animals included marked deposition of immune
complexes containing C3 in glomerular subendothelial,
mesangial and subepithelial locations and glomerular
inflammation with infiltrated neutrophils and macro-
phages [21]. Complement has complicated and paradox-
ical roles in SLE. Although deficiencies of early
components of the complement cascade are associated
with development of SLE due to their role in clearance
of dying cells and tissue debris [7] and their importance
in development of tolerance [22], clearance of immune
complexes [23] and cytokine regulation [24], activation
of complement at later stages of C3 and beyond also
contributes to the pathogenesis of SLE. Studies using
experimental models showed that development of lupus
nephritis was dependent on generation of C5a in glo-
meruli [25] and on the presence of iC3b in glomerular
immune complexes [26]. Such observed complement
activation in glomerulus was triggered by immune com-
plexes. MCP and FH are both localized to glomerular
capillary walls, where they attenuate complement activa-
tion under normal conditions. However, this level of
protection may be compromised by inherited or
acquired deficiency of these proteins.
The A353V polymorphism in MCP has previously
been shown to affect the ability of MCP to control the
alternative pathway activation [27]. This conservative
amino acid substitution in the transmembrane domain
did not affect the ability of recombinant MCP to bind
C3b/C4b and to act as a cofactor to FI in the fluid
phase. The mutant was defective in its regulatory activ-
ity, however, when embedded in the membrane -
although the mechanism underlying this impairment of
function was not defined. The A353V polymorphism
has been identified in several patients with renal pathol-
ogy such as aHUS, glomerulonephritis with C3 deposits
and HELLP syndrome (hemolysis, elevated liver
enzymes, and low platelets) [27]. We did not detect
association of this polymorphism with SLE in general or
SLE nephritis in the current study, however, and we
found the polymorphism in 5.8% healthy controls ana-
lyzed in the present study and in 3.1% of 192 healthy
controls of Caucasian origin included in the study of
spontaneous pregnancy loss (manuscript in preparation,
Mohlin F, Mercier E, Fremeaux-Bacchi V, Liszewski K,
Atkinson JP, Gris JC, Blom AM). The NCBI database
estimates 2% frequency for this SNP in European popu-
lations [28]. Taken together, these frequencies suggests
that the A353V polymorphism in MCP cannot be a
strong causative factor for SLE/SLE nephritis, and most
probably not aHUS either, but could be a modifying fac-
tor in the presence of additional defects in complement
regulation often observed in these patients.
The CD46ggaac haplotype has been previously shown
to be overrepresented in aHUS patients compared with
controls (odds ratio = 2.68). Interestingly, this associa-
tion was mainly due to the aHUS patients with muta-
tions in CFH, CD46 or CFI (odds ratio = 5.25), whereas
aHUS patients without identified mutations in CFH,
CD46 or CFI showed no differences with the control
group [17]. The functional consequences of the five
synonymous SNPs in the CD46ggaac haplotype have not
been fully elucidated, but it has been shown that the
rs2796267 and the rs2796268 SNPs located in the pro-
moter region are involved in the transcriptional activity
potentially due to disruption of the CBF-1/RBP-Jk bind-
ing site [17]. Two other SNPs in the CD46ggaac haplo-
type block are intronic, while the third lies in the 3’
U T R .I nt h ec u r r e n ts t u d yw ef o u n dw e a ki n d i c a t i o n
that the CD46ggaac haplotype could perhaps be protec-
tive for SLE, and in particular SLE with nephritis,
whereas the CD46agaac could represent a risk haplotype.
These indications must now be assessed in a larger
patient material before final conclusions are made.
Several nonsynonymous polymorphisms in CFH have
been linked to age-related macular degeneration [29,30]
and susceptibility to meningococcal disease [31], but not
to rheumatoid arthritis [32] or coronary heart disease
[33]. A large number of studies have shown that I62V
polymorphism in CCP1 of FH affects its FI cofactor
activity and ability to accelerate decay of convertases
[34,35] and that the Y402H polymorphism in CCP7
affects binding of FH to several ligands such as C-reac-
tive protein, DNA, dying cells and heparin [36,37]. The
effect of the D936E polymorphism in CCP16, however,
has not yet been analyzed. In the current study we did
not detect any significant associations with these three
SNPs in CFH nor any of the haplotypes thereof. This
finding is consistent with a recent publication assessing
association of genetic variants in CFH with SLE suscept-
ibility [38]. The authors studied 60 SNPs covering CFH
and FH-related genes for association with SLE in over
15,000 case-control subjects from four ethnic groups.
They found significant allelic associations with SLE in
European Americans and African Americans, which
could be attributed to an intronic CFH SNP and inter-
genic SNP between CFHR1 and CFHR4 rather than the
exonic SNPs we studied.
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Taken together, SLE and SLE nephritis do not appear to
be associated with frequent mutations in CD46 or CFH
as reported for some other kidney diseases, but these
mutations are likely to affect the year of onset of nephri-
tis. Furthermore, the role of CD46 haplotypes still
remains to be elucidated in a larger patient cohort.
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